|
|
|
|
What is Boehringer Ingelheim's policy on clinical trial information disclosure?
Boehringer Ingelheim has a general policy of
transparency with publication of clinical trial results. We recognize that
there are important public health benefits associated with making clinical trial
information more widely available to healthcare professionals and patients. Such
disclosure, however, must maintain protection for intellectual property and
contract rights as well as conform to the regulations in relevant countries.
Boehringer Ingelheim supports the joint global position of
the research-based pharmaceutical industry published by the International
Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on 06
January 2005 and is committed to the agreed principles.
Related content
IFPMA: joint global position as published on 06 January 2005 entitled "
Global
Industry Position On Disclosure of Information About Clinical Trials"
© 2005 - 2007 Boehringer Ingelheim International GmbH, Germany. All rights reserved.
|
|
|
|
|
|
Glossary of Terms
|
Looking for key terms in connection with
clinical trials, like Blinding? Direct
Access? Or other terms?
See our
Glossary of Terms section. |
|
|
|
|
|
FAQs |
What is a clinical trial?
What are the phases of clinical trials?
Look for answers to your questions in our
FAQ section. |
|
